Abstract: Disclosed herein are antisecretory agents represented by the formula ##STR1## wherein R.sup.1 is hydrogen and R.sup.2 is lower alkylthio, (2-thienylmethyl)thio or SCH.sub.2 -- COOR.sup.5 wherein R.sup.5 is hydrogen or lower alkyl, or R.sup.1 and R.sup.2 are independently a lower alkylthio or (2-thienylmethyl)thio, or R.sup.1 and R.sup.2 together with the carbon atom to which they are attached form a 2-imidazolidinylidene; and R.sup.3 and R.sup.4 are each the same lower alkyl, or R.sup.3 and R.sup.4 together with the carbon atoms to which they are attached form a cyclohexane wherein said carbon atom is a spiro atom in common with the cyclohexane ring and the adjoining dioxane ring.

Abstract: A process and intermediates for preparing 6-(lower alkoxy)-5-(trifluoromethyl)-1-naphthalenecarboxylic acid derivatives are disclosed. The derivatives are useful for preparing aldose reductase inhibitors. With reference to the process, 1,1,1-trifluoro-5-(2-methylphenyl)-2,3-pentadione 3-oxime is cyclized to give a key intermediate 3,4-dihydro-1-hydroxy-5-methyl-1-(trifluoromethyl)-2(1H)-naphthalenone oxime; and 3,4-dihydro-1-hydroxy-5-methyl-1-(trifluoromethyl)-2(1H)-naphthalenone is aromatized to 5-methyl-1-(trifluoromethyl)-2-naphthalenol with a dehydrating agent.

Abstract: Disclosed herein are new aldose reductase inhibitors of the formula ##STR1## wherein R is ##STR2## wherein R.sup.1 is lower alkyl; R.sup.2 is halo and R.sup.3 is hydrogen, or R.sup.2 and R.sup.3 each is a substituent at positions 3, 4, 5 or 6 of the naphthalene ring selected from the group consisting of lower alkoxy, trihalomethyl, and halo; and R.sup.4 is lower alkyl. The derivatives are useful for treating or preventing diabetic complications.

Abstract: Herein disclosed are N-naphthoylglycine derivatives having aldose reductase inhibiting activity. The derivatives are useful for treating diabetic complications.

Abstract: A process and intermediates for preparing 6-(lower alkoxy)-5-(trifluoromethyl)-1-naphthalenecarboxylic acid derivatives are disclosed. The derivatives are useful for preparing aldose reductase inhibitors. With reference to the process, 1,1,1-trifluoro-5-(2-methylphenyl)-2,3-pentadione 3-oxime is cyclized to give a key intermediate 3,4-dihydro-1-hydroxy-5-methyl-1-(trifluoromethyl)-2(1H)-naphthalenone oxime; and 3,4-dihydro-1-hydroxy-5-methyl-1-(trifluoromethyl)-2(1H)-naphthalenone is aromatized to 5-methyl-1-(trifluoromethyl)-2-naphthalenol with a dehydrating agent.

Abstract: Herein disclosed are N-(naphthalenylthioxomethyl)aminoacid derivatives having aldose reductase inhibiting activity. The derivatives are useful for treating diabetic complications.

Abstract: Aldose reductase inhibitors of the formula ##STR1## wherein R.sup.1 and R.sup.2 each is lower alkyl, or a therapeutically acceptable salt thereof with an organic or inorganic base, are useful for treating diabetic complications.

Abstract: Herein is described a process for preparing the decapeptide Pry-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH.sub.2 ([D-Trp.sup.6 ]-LH-RH) by coupling Pyr-His-Trp-NHNH.sub.2 with H-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH.sub.2. [D-Trp.sup.6 ]-LH-RH had been established to be an efficient agent for causing release of lutenizing hormone and follicle-stimulating hormone in mammals.

Abstract: Peptides of formula I ##STR1## in which X is (CH.sub.2).sub.2, S--CH.sub.2 or CH.sub.2 --S or a therapeutically acceptable acid addition salt thereof are disclosed. The peptides of formula I are useful as agents for the treatment of acromegaly and the management of diabetes in a mammal. Compositions and methods for the preparation of the peptides of formula I are also disclosed.

Abstract: Compounds of the formula HSCH.sub.2 CHR.sup.1 CO--Pro--R.sup.2 --R.sup.3 --OH in which R.sup.1 is hydrogen or lower alkyl, R.sup.2 is an amino acid residue exclusive of prolyl and R.sup.3 is an amino acid residue exclusive of glutamyl are useful for alleviating angiotensin related hypertension.